Evaluation of the correlation of oxytocin plasma levels and metabolic syndrome biomarkers (Leptin, adiponectin and resistin) in newly diagnosed type 2 diabetes patients in Jordan: A cross sectional study

Levels of oxytocin (OXT) hormone and inflammatory biomarkers (leptin, resistin and adiponectin) were measured in 166 plasma samples of Metabolic Syndrome (MS) patients (1) that visited the outpatients’ endocrinology clinics, Jordan University Hospital (JUH). Patients were subdivided into two arms according to their glucose profile status, subjects with glucose profile disturbances and normoglycemic subjects. MS biomarkers were significantly different (P<0.01) between study groups, mean OXT levels (ng/mL) were exceptionally higher (p<0.01) in MS-control group (2.25+0.85) than in MS-pre/T2DM group (1.20+0.50). Conversely, in comparison to MS-controls; MS-pre/T2DM patients had significantly higher adipocytokines plasma levels; namely resistin was 13 times higher (ng/mL) (82.05+ 32.44 vs. 6.45+4.39); leptin two times higher (ng/mL) (42.43+30.44 vs. 22.76+14.19) and adiponectin was 3-fold higher (µg/mL) (6.869+1.082 vs. 1.97+0.606). These findings were indicative for the potential pharmacologic benefit of this hormone in minimization of inflammatory markers chronic deleterious effect.